Literature DB >> 25576879

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

M A Karsdal1, A Bihlet2, I Byrjalsen2, P Alexandersen3, C Ladel4, M Michaels4, J R Andersen2, B J Riis2, V Kraus5, A C Bay-Jensen2, C Christiansen2.   

Abstract

BACKGROUND/
PURPOSE: The aim of this study was to identify key characteristics of disease progression through investigation of the association of radiographic progression over two years with baseline Joint Space Width (JSW), Kellgren-Lawrence (KL) grade, Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain, Joint Space Narrowing (JSN), and BMI.
METHODS: Data from 2206 subjects (4390 knees) were combined for this post-hoc analysis of two randomized, double-blind, multi-center, placebo-controlled phase III trials (NCT00486434 and NCT00704847) that evaluated the efficacy and safety of 2-years treatment with oral salmon calcitonin of subjects with painful knee osteoarthritis (OA).
RESULTS: There was a clear positive and significant correlation between KL grade and WOMAC pain and total WOMAC, albeit the variance in pain measures was from min-to-max for all KL categories, emphasizing the heterogeneity of this patient population and pain perception. 32% of target knees did not progress, and only 51% had changes over minimum significant change (MSC). BMI, KL-Score and WOMAC pain was diagnostic, but only KL-score and pain had prognostic value, albeit pain in a non-linear manner.
CONCLUSION: These data clearly describe significant associations between KL grade, JSW, pain and BMI in patients with symptomatic knee OA. KL grade, BMI and WOMAC pain were diagnostically associated with OA based on JSW but only KL-score and pain in a non-linier fashion was prognostic. 50% of patients did not progress more than MSC, highlighting the importance for identification of structural progressors and the phenotypes associated with these. These results suggest that disease phenotypes, rather than disease status, are responsible for disease progression.
Copyright © 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; Clinical; Diagnosis; Osteoarthritis; PhaseIII; Progression

Mesh:

Substances:

Year:  2015        PMID: 25576879     DOI: 10.1016/j.joca.2014.12.024

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  19 in total

1.  The incident tibiofemoral osteoarthritis with rapid progression phenotype: development and validation of a prognostic prediction rule.

Authors:  D L Riddle; P W Stratford; R A Perera
Journal:  Osteoarthritis Cartilage       Date:  2016-07-05       Impact factor: 6.576

2.  A quantitative metric for knee osteoarthritis: reference values of joint space loss.

Authors:  C Ratzlaff; E L Ashbeck; A Guermazi; F W Roemer; J Duryea; C K Kwoh
Journal:  Osteoarthritis Cartilage       Date:  2018-05-26       Impact factor: 6.576

3.  Characterization of synovial fluid metabolomic phenotypes of cartilage morphological changes associated with osteoarthritis.

Authors:  A K Carlson; R A Rawle; C W Wallace; E G Brooks; E Adams; M C Greenwood; M Olmer; M K Lotz; B Bothner; R K June
Journal:  Osteoarthritis Cartilage       Date:  2019-04-25       Impact factor: 6.576

Review 4.  Is osteoarthritis one disease or a collection of many?

Authors:  Leticia A Deveza; Richard F Loeser
Journal:  Rheumatology (Oxford)       Date:  2018-05-01       Impact factor: 7.580

5.  MRI-based screening for structural definition of eligibility in clinical DMOAD trials: Rapid OsteoArthritis MRI Eligibility Score (ROAMES).

Authors:  F W Roemer; J Collins; C K Kwoh; M J Hannon; T Neogi; D T Felson; D J Hunter; J A Lynch; A Guermazi
Journal:  Osteoarthritis Cartilage       Date:  2019-09-09       Impact factor: 6.576

6.  Low-grade inflammation in symptomatic knee osteoarthritis: prognostic value of inflammatory plasma lipids and peripheral blood leukocyte biomarkers.

Authors:  Mukundan Attur; Svetlana Krasnokutsky; Alexander Statnikov; Jonathan Samuels; Zhiguo Li; Olga Friese; Marie-Pierre Hellio Le Graverand-Gastineau; Leon Rybak; Virginia B Kraus; Joanne M Jordan; Constantin F Aliferis; Steven B Abramson
Journal:  Arthritis Rheumatol       Date:  2015-11       Impact factor: 10.995

Review 7.  The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA.

Authors:  Frank W Roemer; C Kent Kwoh; Daichi Hayashi; David T Felson; Ali Guermazi
Journal:  Nat Rev Rheumatol       Date:  2018-06       Impact factor: 20.543

8.  Plasma levels of interleukin-1 receptor antagonist (IL1Ra) predict radiographic progression of symptomatic knee osteoarthritis.

Authors:  M Attur; A Statnikov; J Samuels; Z Li; A V Alekseyenko; J D Greenberg; S Krasnokutsky; L Rybak; Q A Lu; J Todd; H Zhou; J M Jordan; V B Kraus; C F Aliferis; S B Abramson
Journal:  Osteoarthritis Cartilage       Date:  2015-11       Impact factor: 6.576

9.  Association between disease progression and depression onset in persons with radiographic knee osteoarthritis.

Authors:  Alan M Rathbun; Michelle D Shardell; Alice S Ryan; Michelle S Yau; Joseph J Gallo; Megan S Schuler; Elizabeth A Stuart; Marc C Hochberg
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

10.  Depressive symptoms and structural disease progression in knee osteoarthritis: data from the Osteoarthritis Initiative.

Authors:  Alan M Rathbun; Michelle S Yau; Michelle Shardell; Elizabeth A Stuart; Marc C Hochberg
Journal:  Clin Rheumatol       Date:  2016-12-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.